Stock Events

Stock Events

Cell Source 

$0.65
6
-$0.15-18.25% Tuesday 15:03

Statistics

Day High
0.76
Day Low
0.65
52W High
2.25
52W Low
0.18
Volume
1,120
Avg. Volume
4,758
Mkt Cap
29.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2NovExpected
Q3 2020
Q1 2021
Q2 2021
Q2 2021
Q3 2021
Q1 2022
Q3 2022
-0.06
-0.04
-0.02
0
Expected EPS
0
Actual EPS
-0.05

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-12.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLCS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Cell Source's cell therapy innovations.
Novartis
NVS
Mkt Cap237.61B
Novartis offers CAR-T cell therapies, directly competing with Cell Source's cell therapy approaches for cancer.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T therapy space, similar to Cell Source's offerings.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on gene therapy, which could serve as an alternative to Cell Source's therapeutic strategies.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genome editing, a competing field to Cell Source's cell therapy and regenerative medicine.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies focuses on immune-driven medicine, potentially competing with Cell Source's immune system modulation therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is involved in allogeneic CAR-T cell therapies, a direct competitor to Cell Source's personalized cell therapies.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is developing programmed cellular immunotherapies, competing in the same space as Cell Source.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is engaged in various biopharmaceutical innovations, including cell therapy, posing a broad competitive landscape to Cell Source.

About

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Show more...
CEO
Dr. Dennis M. Brown B.Sc., M.A., Ph.D.
Employees
1
Country
US
ISIN
US15114L1044

Listings

OTC Link
US
CLCS

0 Comments

Share your thoughts

FAQ

What is Cell Source stock price today?▼
The current price of CLCS is $0.65 USD — it has decreased by -18.25% in the past 24 hours. Watch Cell Source stock price performance more closely on the chart.
What is Cell Source stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cell Source stocks are traded under the ticker CLCS.
Is Cell Source stock price growing?▼
CLCS stock has fallen by -14.39% compared to the previous week, the month change is a -31.87% fall, over the last year Cell Source has showed a +94.64% increase.
What is Cell Source market cap?▼
Today Cell Source has the market capitalization of 29.45M
What were Cell Source earnings last quarter?▼
CLCS earnings for the last quarter are -0.05 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cell Source revenue for the last year?▼
Cell Source revenue for the last year amounts to 0 USD.
What is Cell Source net income for the last year?▼
CLCS net income for the last year is -12.29M USD.
How many employees does Cell Source have?▼
As of April 01, 2026, the company has 1 employees.
In which sector is Cell Source located?▼
Cell Source operates in the Health Care sector.
When did Cell Source complete a stock split?▼
Cell Source has not had any recent stock splits.
Where is Cell Source headquartered?▼
Cell Source is headquartered in New York, US.